Matinas BioPharma Holdings Inc (AMEX:MTNB)

$ 0.55 -0.0174 (-3.07%) Market Cap: 2.76 Mil Enterprise Value: -8.23 Mil PE Ratio: 0 PB Ratio: 0.14 GF Score: 57/100

Q2 2024 Matinas BioPharma Holdings Inc Earnings Call Transcript
Aug 14, 2024

$7.85 (+1.29%)

Earnings
Q4 2023 Matinas BioPharma Holdings Inc Earnings Call Transcript
Mar 27, 2024

$14.5 (+1.47%)

Earnings
Matinas BioPharma Holdings Inc At The Biotech Showcase Transcript
Jan 09, 2024
Q3 2023 Matinas BioPharma Holdings Inc Earnings Call Transcript
Nov 08, 2023

$13.8 (-13.78%)

Earnings
Matinas BioPharma Holdings Inc Annual Shareholders Meeting Transcript
Nov 01, 2023
Q2 2023 Matinas BioPharma Holdings Inc Earnings Call Transcript
Aug 09, 2023

$16.5 (-0.72%)

Earnings
Q1 2023 Matinas BioPharma Holdings Inc Earnings Call Transcript
May 10, 2023

$33.5 (+8.06%)

Earnings
Q4 2022 Matinas BioPharma Holdings Inc Earnings Call Transcript
Mar 15, 2023

$21.5 (-4.44%)

Earnings
Matinas BioPharma Holdings Inc To Discuss The Business Outlook Call Transcript
Jan 30, 2023
Q3 2022 Matinas BioPharma Holdings Inc Earnings Call Transcript
Nov 02, 2022

$39.25 (+0.15%)

Earnings
Q2 2022 Matinas BioPharma Holdings Inc Earnings Call Transcript
Aug 11, 2022

$42.34 (-4.22%)

Earnings
Q1 2022 Matinas BioPharma Holdings Inc Earnings Call Transcript
May 12, 2022

$32.04 (+2.01%)

Earnings
Matinas BioPharma Holdings Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 13, 2022
Q4 2021 Matinas BioPharma Holdings Inc Earnings Call Transcript
Mar 08, 2022

$29 (+5.44%)

Earnings
Matinas BioPharma Holdings Inc To Provide Corporate Update And 2022 Business Outlook Call Transcript
Jan 25, 2022
Q3 2021 Matinas BioPharma Holdings Inc Earnings Call Transcript
Nov 08, 2021

$50.5 (-5.61%)

Earnings
Matinas BioPharma Holdings Inc To Discuss EnACT Topline Data Call Transcript
Sep 13, 2021
Q2 2021 Matinas BioPharma Holdings Inc Earnings Call Transcript
Aug 10, 2021

$36.56 (-5.03%)

Earnings
Matinas BioPharma Holdings Inc R&D Day Transcript
Jun 17, 2021
Q1 2021 Matinas BioPharma Holdings Inc Earnings Call Transcript
May 10, 2021

$38.48 (-2.67%)

Earnings
Q4 2020 Matinas BioPharma Holdings Inc Earnings Call Transcript
Mar 29, 2021

$53 (-5.36%)

Earnings
Matinas BioPharma Holdings Inc at Barclays Global Healthcare Conference (Virtual) Transcript
Mar 09, 2021
Matinas BioPharma Holdings, Inc. - Special Call Transcript
Feb 01, 2021
Q3 2020 Matinas BioPharma Holdings Inc Earnings Call Transcript
Nov 06, 2020

$42.3 (+0.06%)

Earnings
Matinas BioPharma Holdings Inc Annual Shareholders Meeting Transcript
Nov 02, 2020
Q2 2020 Matinas BioPharma Holdings Inc Earnings Call Transcript
Aug 10, 2020

$46.15 (+3.82%)

Earnings
Matinas BioPharma Holdings Inc at Jefferies Healthcare Conference (Virtual) Transcript
Jun 02, 2020
Q1 2020 Matinas BioPharma Holdings Inc Earnings Call Transcript
May 11, 2020

$38.19 (+11.65%)

Earnings
Q4 2019 Matinas BioPharma Holdings Inc Earnings Call Transcript
Mar 09, 2020

$47 (-11.33%)

Earnings
Q3 2019 Matinas BioPharma Holdings Inc Earnings Call Transcript
Nov 13, 2019

$45.07 (-4.62%)

Earnings
Q2 2019 Matinas BioPharma Holdings Inc Earnings Call Transcript
Aug 13, 2019

$35.58 (+9.39%)

Earnings
Q1 2019 Matinas BioPharma Holdings Inc Earnings Call Transcript
May 14, 2019

$47.42 (+5.37%)

Earnings
Full Year 2018 Matinas BioPharma Holdings Inc Earnings Call Transcript
Apr 02, 2019

$53 (-4.50%)

Earnings

Matinas BioPharma Holdings Inc at Needham Healthcare Conference (Virtual) Transcript

Apr 13, 2022 / 07:00PM GMT

Release Date Price: $44.31 (+2.87%)

Transcript

Chang Liu

Needham & Company, LLC - Analyst

Good afternoon, and welcome to the 21st Needham Healthcare Conference. My name is Chang Liu, and I will be the moderator for this presentation. We welcome Matinas BioPharma here today and its CEO, Jerry Jabbour. (Conference Instructions)

Without further ado, Jerry, would you like to start your presentation?

Jerry Jabbour

Matinas BioPharma Holdings, Inc. - CEO

Great. Chang, thanks so much. As Chang mentioned, I'm Jerry Jabbour, Co-Founder and CEO of Matinas, and we're thrilled to be here at the Needham 21st Annual Virtual Healthcare Conference. It's been a big week for our company, an exciting week for our company as we've had some validating news, which we think reflects not only the interest, but the data that's already been generated to date with our lipid nanocrystal or LNC delivery platform. And so I'm very grateful to have the opportunity today really for the first time publicly to address these latest developments, walk you through our overall business strategy and some of the exciting things we

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.